|
Inflammatory Bowel Diseases
|
0.700 |
GeneticVariation
|
group |
BEFREE |
IL-10-deficient mice and patients with mutations in IL-10 or its receptor, IL-10R, show increased susceptibility to inflammatory bowel diseases (IBD).
|
31194881 |
2019 |
|
Inflammatory Bowel Diseases
|
0.700 |
AlteredExpression
|
group |
BEFREE |
Employing a TNFα-driven murine inflammatory bowel disease (IBD) model (TNF<sup>ΔARE/+</sup>), which mirrors the Treg expansion and transmural ileitis seen in Crohn's disease, we demonstrate that the TNFα-mediated loss of Treg suppressive function coincides with induction of a specific miRNA, miR-106a in both humans and mice, via NFκB promoter binding to suppress post-transcriptional regulation of IL-10 release.
|
30327532 |
2019 |
|
Inflammatory Bowel Diseases
|
0.700 |
GeneticVariation
|
group |
BEFREE |
Phenotypic Characterization of Very Early-Onset Inflammatory Bowel Disease with Interleukin-10 Signaling Deficiency: Based on a Large Cohort Study.
|
30212871 |
2019 |
|
Inflammatory Bowel Diseases
|
0.700 |
GeneticVariation
|
group |
BEFREE |
IBD in infants and children under 2 years of age is life-threatening when patients with IL-10R mutations do not receive allogeneic HSCT.
|
30900524 |
2019 |
|
Inflammatory Bowel Diseases
|
0.700 |
Biomarker
|
group |
BEFREE |
Moreover, in Il10-deficient mice with inflammatory bowel disease and normal kidney function, plasma FGF23 was elevated and normalized upon TNF neutralization.
|
31301888 |
2019 |
|
Inflammatory Bowel Diseases
|
0.700 |
Biomarker
|
group |
BEFREE |
<i>Enterococcus faecalis</i> is a resident member of the human intestinal core microbiota that has been linked to the pathogenesis of IBD and induces chronic colitis in susceptible monoassociated IL-10-deficient (IL-10<sup>-/-</sup>) mice.
|
31281321 |
2019 |
|
Inflammatory Bowel Diseases
|
0.700 |
Biomarker
|
group |
BEFREE |
The apolipoprotein A-I (APOA1) mimetic 4F mitigated disease in both the Cox2 MKO/CCHF and piroxicam-accelerated Il10-/- models of inflammatory bowel disease (IBD) and reduced elevated levels of pro-inflammatory mediators in tissue and plasma.
|
31184596 |
2019 |
|
Inflammatory Bowel Diseases
|
0.700 |
Biomarker
|
group |
BEFREE |
This is the first study investigating consequences of hydromorphone in both dextran sodium sulfate (DSS)-induced colitis and spontaneous colitis [IL-10 knockout (IL-10-/-)] mouse model of IBD.
|
31773170 |
2019 |
|
Inflammatory Bowel Diseases
|
0.700 |
Biomarker
|
group |
BEFREE |
These data indicate that butyrate controls the capacity of T cells in the induction of colitis by differentially regulating Th1 and Th17 cell differentiation and promoting IL-10 production, providing insights into butyrate as a potential therapeutic for the treatment of inflammatory bowel disease.
|
30918945 |
2019 |
|
Inflammatory Bowel Diseases
|
0.700 |
Biomarker
|
group |
BEFREE |
A better understanding of how IL-10 exerts its suppressive function may allow identification of individuals with suboptimal IL-10 function among the heterogeneous population of IBD patients.
|
31417161 |
2019 |
|
Inflammatory Bowel Diseases
|
0.700 |
Biomarker
|
group |
BEFREE |
Collectively, our work identifies Shp2 as a detrimental factor for intestinal immune homeostasis and hopefully will be helpful in the future exploitation of IL-10 immunotherapy for IBD.
|
30610104 |
2019 |
|
Inflammatory Bowel Diseases
|
0.700 |
Biomarker
|
group |
BEFREE |
Previously, we found that IL-13Rα2 was necessary for IBD in mice deficient in the anti-inflammatory cytokine IL-10.
|
31308480 |
2019 |
|
Inflammatory Bowel Diseases
|
0.700 |
Biomarker
|
group |
BEFREE |
We assessed the effect of B. thetaiotaomicron administration on primary readouts of colitis (weight loss, histopathology, and immune parameters) in dextran sodium sulphate (DSS) and interleukin-10 knockout (IL10KO) models of IBD.
|
30215718 |
2019 |
|
Inflammatory Bowel Diseases
|
0.700 |
Biomarker
|
group |
BEFREE |
The TGF-β-induced Tregs that express IL-10 blocked colitis when transferred into the Rag/CD25<sup>-</sup> CD4<sup>+</sup> T cell transfer model of inflammatory bowel disease.
|
30850474 |
2019 |
|
Inflammatory Bowel Diseases
|
0.700 |
GeneticVariation
|
group |
BEFREE |
In the present study, we report a novel homozygous null mutation within interleukin-10 receptor B (IL10RB) gene in a child presenting with severe VEO-IBD.
|
31096038 |
2019 |
|
Lupus Erythematosus, Systemic
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Moreover, IL-10 was found to be highly expressed in SLE patients by ELISA.
|
30991045 |
2019 |
|
Lupus Erythematosus, Systemic
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Lymphocytes with bound platelets from both HD and SLE patients had major levels of CD86 and BAFFR and a greater production of IL-10 than lymphocytes without bound platelets.
|
30944545 |
2019 |
|
Lupus Erythematosus, Systemic
|
0.700 |
Biomarker
|
disease |
BEFREE |
INF1α, IL-10 and BLyS are higher in SLE patients than in healthy controls (P<.001, P=.005 and P=.043, respectively), being INF1α the most frequent.
|
30795903 |
2019 |
|
Lupus Erythematosus, Systemic
|
0.700 |
Biomarker
|
disease |
BEFREE |
These results suggest that dysregulated type I IFNs in cDCs contribute to the increased IL-10 and IL-27 in SLE.
|
31216373 |
2019 |
|
Lupus Erythematosus, Systemic
|
0.700 |
Biomarker
|
disease |
BEFREE |
A better understanding of the role of IL-10 in B-cell responses and lupus would allow to identify the most promising therapies for individual SLE patients in the future.
|
31735515 |
2019 |
|
Lupus Erythematosus, Systemic
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
The absence of CD137L causes an immune deviation toward Th17, fewer IL-10-producing CD11b<sup>+</sup> cells and reduced serum IL-10 levels which potentially explain the more severe lupus in DKO mice while leading to reduced microglia activation, lesser cerebral damage and less severe neurological deficits.
|
31297111 |
2019 |
|
Lupus Erythematosus, Systemic
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
We also observed higher plasma levels of IL-10 and TNF α in APA<sup>+</sup> SLE and APS<sup>+</sup> SLE patients when compared with HCs.
|
30729698 |
2019 |
|
Lupus Erythematosus, Systemic
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
A decreased risk of SLE in the IL10-819C/T and IL10-592C/A polymorphisms in subgroups was also observed, but further rigorously studies are needed to confirm these results.
|
30183604 |
2019 |
|
Lupus Erythematosus, Systemic
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
This study demonstrated that the IL-9, IL-10 and IL-25 had significantly increased expressions in SLE-LN, followed by SLE without LN, compared to healthy controls.
|
31697750 |
2019 |
|
Lupus Erythematosus, Systemic
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Anti-inflammatory cytokines included IL-4 IL-10, which were upregulated in SLE-I sera (but not SLE-A), controlling clinical phenotypes.
|
31781106 |
2019 |